A novel single nucleotide polymorphism altering stability and activity of CYP2A6

被引:82
作者
Ariyoshi, N
Sawamura, Y
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Maruyama Clin, Sapporo, Hokkaido 0640820, Japan
关键词
cytochrome P450; genetic polymorphism; nicotine; genetic linkage; genotyping; allele specific PCR; poor metabolizers;
D O I
10.1006/bbrc.2001.4422
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CYP2A6 is known as a major cytochrome P450 (CYP) responsible for the oxidation of nicotine and coumarin in humans. In this study, we explored genetic polymorphisms, which reduce CYP2A6 activity in Japanese. Two novel mutations in exon 9 of the CYP2A6 gene were found. A single nucleotide polymorphism of T1412C and G1454T resulted in Ile471Thr and Arg485Leu substitution, respectively. The frequency of the former variant allele was considerably high (15.7%), while the latter variant appeared to be a rare polymorphism. Heterologous expression of CYP2A6 using a cDNA possessing C instead of T-base at codon 471 in Escherichia coli caused remarkable reduction of the stability of holoenzyme at 37 degreesC. Furthermore, this variant enzyme almost lacked nicotine C-oxidase activity, although coumarin 7-hydroxylase activity was still observed. These data suggest that individuals homozygous for the T1412C variant allele or heterozygous for this and a defect allele such as the CYP2A6*4 may be poor metabolizer of nicotine, but not coumarin. (C) 2001 Academic Press.
引用
收藏
页码:810 / 814
页数:5
相关论文
共 17 条
  • [1] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
    Ariyoshi, N
    Takahashi, Y
    Miyamoto, M
    Umetsu, Y
    Daigo, S
    Tateishi, T
    Kobayashi, S
    Mizorogi, Y
    Loriot, MA
    Stücker, I
    Beaune, P
    Kinoshita, M
    Kamataki, T
    [J]. PHARMACOGENETICS, 2000, 10 (08): : 687 - 693
  • [2] GOTOH O, 1992, J BIOL CHEM, V267, P83
  • [3] GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596
  • [4] High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli
    Iwata, H
    Fujita, K
    Kushida, H
    Suzuki, A
    Konno, Y
    Nakamura, K
    Fujino, A
    Kamataki, T
    [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) : 1315 - 1325
  • [5] MESSINA ES, 1997, J PHARMACOL EXP THER, V282, P1618
  • [6] CYP2A6 gene deletion reduces susceptibility to lung cancer
    Miyamoto, M
    Umetsu, Y
    Dosaka-Akita, H
    Sawamura, Y
    Yokota, J
    Kunitoh, H
    Nemoto, N
    Sato, K
    Ariyoshi, N
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (03) : 658 - 660
  • [7] Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212
  • [8] Nunoya K, 1999, J PHARMACOL EXP THER, V289, P437
  • [9] Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype
    Nunoya, K
    Yokoi, T
    Takahashi, Y
    Kimura, K
    Kinoshita, M
    Kamataki, T
    [J]. JOURNAL OF BIOCHEMISTRY, 1999, 126 (02) : 402 - 407
  • [10] Nunoya KI, 1996, J PHARMACOL EXP THER, V277, P768